Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MoonLake Immunotherapeutics
MLTX | US
18.32
USD0.17
0.94%
MLTX | US
Loading StockChartView...
About MoonLake Immunotherapeutics
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
18.32
Open
18.07
High
18.80
Low
17.93
MoonLake Immunotherapeutics a clinical-stage biopharmaceutical company engages in developing therapies. It is developing Sonelokimab a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa psoriatic arthritis ankylosing spondylitis or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug Switzerland.
View LessMLTX | US
Risk
49.1
Sharpe
-0.51
Luna's Score
43/100
Recommendation
Sell
Luna says (MLTX | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
25.3%1 month
49.1%3 months
97.7%6 months
155.2%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
5.91
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
-41.53
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-78.35M
MarketCap
1.15B
MarketCap(USD)
1.15B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-11.32
Short ratio
26.00
Short perc.
30.86
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
2.49
Range1M
4.26
Range3M
8.43
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.72
Price X volume
16.95M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -41.53 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 5.91 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 97.73 | 72.80 | Riskier |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 1.15B | 3.66B | Emerging |
